Management of long-term complications from immunosuppression
- PMID: 38315054
- DOI: 10.1097/LVT.0000000000000341
Management of long-term complications from immunosuppression
Abstract
This review discusses long-term complications from immunosuppressants after liver transplantation and the management of these complications. Common complications of calcineurin inhibitors include nephrotoxicity and metabolic diseases. Nephrotoxicity can be managed by targeting a lower drug level and/or adding an immunosuppressant of a different class. Metabolic disorders can be managed by treating the underlying condition and targeting a lower drug level. Gastrointestinal adverse effects and myelosuppression are common complications of antimetabolites that are initially managed with dose reduction or discontinuation if adverse events persist. Mammalian targets of rapamycin inhibitors are associated with myelosuppression, proteinuria, impaired wound healing, and stomatitis, which may require dose reduction or discontinuation. Induction agents and agents used for steroid-refractory rejection or antibody-mediated rejection are reviewed. Other rare complications of immunosuppressants are discussed as well.
Copyright © 2024 American Association for the Study of Liver Diseases.
References
-
- Accessed September 26, 2023. https://srtr.transplant.hrsa.gov/annual_reports/2020/Liver.aspx
-
- Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl. 2005;11(Suppl 2):S47–S51.
-
- Nevens F, Pirenne J. Renal disease in the allograft recipient. Best Pract Res Clin Gastroenterol. 2020;46-47:101690.
-
- Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity-What the FK? Adv Chronic Kidney Dis. 2020;27:56–66.
-
- Noble J, Terrec F, Malvezzi P, Rostaing L. Adverse effects of immunosuppression after liver transplantation. Best Pract Res Clin Gastroenterol. 2021;54-55:101762.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical